Top of page Skip navigation

'Maximising Returns from Life Science Innovation'

Whether addressing global health challenges, sustainability, economics, or inclusion & equality, there has perhaps never been such collective drive and desire to ensure all stakeholders can participate in, and derive benefit from, scientific and business innovation.

The 2022 Keynote Programme at Genesis will explore how innovation in Life Sciences is leading to inclusive stakeholder rewards.

Tuesday 6 December 2022 - Genesis Eve Networking Drinks

See 'Fringe Events' for more information

Wednesday 7 December 2022 - Preliminary Keynote Programme

08.30: Registration

09.00: Welcome from One Nucleus 

Jon Green, One Nucleus

09.10: Keynote Address: Winners & Losers 2022

Mike Ward, Clarivate

09.30: Panel: Innovative Dealmaking for Innovative Solutions

A discussion to review the latest trends in life science investment and partnering deals, what have previous financing cycles taught us?

Moderator: Lisa Urquhart, Evaluate Vantage
Panellists:
Julie Simmonds, Panmure Gordon
James Fry, Mills & Reeve
Catherine Pickering, iOnctura
Will Walker-Arnott, Charles Stanley Wealth Management
Kate Rowley, Global Bio Fund

10.30: Coffee Break

11.00: www.LifeSciences.2023

Who will be the stakeholders shaping and disrupting the sector in 2023 and beyond?
What – technologies, in R&D, drug delivery or related field will provide the best solutions for patients?
When will we see the impacts of the above take effect?

Moderator: Paul Branthwaite, TranScrip
Laura Lane, Eli Lilly

11.40: Pre-Lunch Debate: This House Believes...The Golden Triangle is a Better Ecosystem to Grow a Life Science Company than Massachusetts

Following the One Nucleus trade visit to Boston in September 2022, the delegation will feedback their views on what they discovered when comparing these two key life science clusters. The debate will close with an audience vote in favour or in opposition to the title statement

Presiding: Mike Ward, Clarivate

Debaters:

Catherine Stace, Domainex
Max Bryan, Bidwells
Michael Chen, Nuclera
John McCafferty, Maxion Therapeutics
Nick Foser, Metrion Biosciences

12.20: Lunch 

13.30: Panel: Is Technology Diversifying Biomedical R&D Outputs?

The ability to generate, collect and analyse data from diverse sources has never advanced more rapidly. The panel will discuss whether this is leading to greater diversity in areas such as target selection & drug design, patient stratification in clinical trials, scale of collaboration and skills 

Moderator: Lisa Melton, Nature Biotechnology 

Panellists:
Rowan Gardner, PrecisionLife
Jackie Hunter OBE, BenevolentAI

Andy Richards, Ieso Digital Health
Niklas Blomberg, ELIXIR Europe

14.20: Panel: Value Creation and Sharing in a Converging World

As R&D evolves to include ever-increasing reliance on Big Data and AI, external partnerships and global markets, how do we collaborate to protect, capture and share the created value equitably?

Moderator: Victoria English, MedNous

Panelists:
Hannah Sore, PharmEnable
Chris Wayman, EY
Claire Smith, Bristows
Nuno Alves, Astellas Pharma

15.00: Coffee break

15.30: So, What Do You Think? 

A chance to listen in to a conversation you wish you had heard as two leading lights share their thoughts on a key question facing the life science sector right now

“Are Diamonds Better Than Gold?’
Claire Thompson, CEO, Agility Life Sciences and Miranda Knaggs, Corporate Development Director, We Are Pioneer Group discuss how the reshaping UK Life Sciences sector could think outside the triangle 

15.50: Panel: The Anatomy of a Life Science Leader

The panel will discuss what successful traits of leadership are required to build an innovation-led Life Science company

Moderator: Mike Ward, Clarivate

Panelists:
Suzanne Holden, Thermo Fisher
Anji Miller, LifeArc
Barry Winkless, Cpl Future of Work Institute
Jacqui Watson, Inivata
Lisa Page, Penningtons Manches Cooper

16.50: Closing remarks

17.00: Drinks Reception

18.00: Close


Headline Sponsor

Sponsors

 

 

 

 

 

 

 

 

Media Supporters